Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)

Background: Mantle cell lymphoma (MCL) accounts for approximately 5-7% of non-Hodgkin lymphomas (NHL). A number of therapies are used for second- and later-line treatment including Bruton’s tyrosine kinase inhibitors (BTKi). However, treatment failure and intolerance are common and alternative thera...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2020-11, Vol.136 (Supplement 1), p.22-23
Hauptverfasser:	Mehta, Amitkumar, Trněný, Marek, Walewski, Jan, Ribrag, Vincent, Dartigeas, Caroline, Christensen, Jacob Haaber, Pane, Fabrizio, Rodríguez, Guillermo, Taszner, Michal, Venugopal, Parameswaran, Zilioli, Vittorio Ruggero, Zheng, Fred, DeMarini, Douglas J, Jiang, Wei, Zinzani, Pier Luigi
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!